Ulcerative colitis (UC), an intractable inflammatory disorder of the colon, is characterized by contiguous inflammation of the colonic lamina propria and is thought to be a type 2 T helper cell (Th2) associated disease. Mast cells are pivotal effector cells in Th2 associated diseases. Upon linkage of the high-affinity immunoglobulin E (IgE) receptors (FceRI) with a complex of allergen and IgE, mast cells are activated and release a large amount of chemical mediators. There are two distinct populations of mast cells, namely, mucosal mast cells and connective tissue mast cells. Recently, there has been considerable evidence demonstrating that mucosal mast cells are morphologically, biochemically, and functionally distinct from connective tissue mast cells. Because deregulated mucosal immune response are thought to be involved in pathogenesis of UC, it is predicted that mucosal mast cells in gut mucosa are more critical in UC etiology than connective tissue mast cells.
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The mast cell count is significantly higher in the colonic mucosa of UC patients than in that of patients with Crohn's disease, Th1 associated inflammatory bowel disease. 1, 2) Mast cells in the colonic mucosa store tryptase in the secretory granules [1] [2] [3] and tryptase secretion is significantly increased in the colonic tissue of UC patients.
3) The result of a pilot study has revealed that systemic administration of APC2059, a specific tryptase inhibitor, is safe and there is evidence of activity in the treatment of UC, 4) suggesting that mucosal mast cells may be greatly involved in the pathogenesis of the inflammatory disease.
In Japan, Japanese herbal medicines of standardized quality, originating from traditional Chinese medicines, so-called Kampo medicines, are widely used for the treatment of various diseases. Among them, saireito, which is often used for the treatment of inflammatory diseases such as rheumatoid arthritis, 5) systemic lupus erythematodes, 5) and nephrotic syndrome, 6) has already been reported to improve the symptoms associated with UC, such as diarrhea and hematochezia; improve the endoscopic findings and quality of life; and reduce the dosage of corticosteroids administered in the combination therapy. 7) However, the precise mechanisms underlying the therapeutic effects of saireito remain largely unclear. Therefore, we examined the effect of saireito on the murine oxazolone-induced colitis model resembling human UC, 8, 9) and demonstrated the therapeutic effect of saireito on the UC model. 9) The transcription levels of Th2 cytokines were significantly upregulated in the colon of the colitis mice. In the colon of the saireito-treated mice, the enhanced expression of the Th2 cytokine mRNAs was markedly downregulated. 9) These results suggest that mucosal mast cells play an important role in gut hypersusceptibility and inflammation in UC, and we hypothesized saireito has direct effects on mucosal mast cell activation. (Table 1) . In this study, we examined the effects of saireito, shosaikoto, goreisan and their constituents on IgEinduced degranulation of mucosal-type mast cells.
MATERIALS AND METHODS
Drugs Saireito (TJ-114, lot No. 2010114010), shosaikoto (TJ-9, lot No. 2040009010), goreisan (TJ-17, lot No. 2030017010) and the dried powder extracts from constituent medicinal plants were purchased from Tsumura Co. (Tokyo, Japan). These drugs were dissolved in distilled water to the concentration of 10 mg/ml, heated at 95°C for 20 min, and centrifuged (12000 g for 10 min) to remove insoluble ingredients. The supernatant was filtrated by using 0.45 mm filters for sterilization and used for culturing cells. Ergosterol (Wako Pure Chemical Industries, Osaka, Japan) was dissolved in MeOH at 2.5 mM, then diluted with culture medium, sonicated for 10 min, and used for culturing cells.
Cell Culture We prepared mucosal-type murine bone marrow-derived mast cells (mBMMCs) from a 5-to 7-weekold male mouse (BALB/c) according to the method described previously. 10, 11) Briefly, bone marrow cells were cultured in RPMI-1640 medium (Sigma, St. Louis, MO, U.S.A.) supplemented with 10% heat-inactivated fetal calf serum (FCS) (JRH Biosciences, Lenexa, KS, U.S.A.), 10 mM 2-mercaptoethanol (Wako Pure Chemical Industries, Osaka, Japan), 20 mM N-(2-hydroxyethyl)piperazine-NЈ-2-ethanesulfonic acid (Hepes) buffer (Sigma), 1 mM sodium pyruvate (Sigma), 100 mM MEM non-essential amino acids (Sigma), 2 mg/ml gentamicin solution (Sigma), 20 ml/ml penicillinstreptomycin solution stabilized (Sigma), 20 ng/ml recombinant murine interleukin-3 (IL-3; Peprotech, London, U.K.), 40 ng/ml recombinant murine SCF (Peprotech), 5 ng/ml recombinant murine IL-9 (Peprotech) and 1 ng/ml transforming growth factor (TGF)-b1 (Peprotech) at 37°C in a humidified 5% CO 2 atmosphere. Mast cell purity was examined by flow cytometry (FACSCalibur; Becton Dickinson, Franklin Lakes, NJ, U.S.A.), and more than 98% of the non-adherent cells were FceRI-and c-kit-positive (data not shown). All animal care and experiments were approved by the Animal Experiment Committee in University of Toyama (Authorization No. is INM-13).
Degranulation Assay The degree of degranulation was assessed by measuring b-hexosaminidase release as previously described.
11) Briefly, mBMMCs were pretreated by different concentrations of the test drugs for 24 h, then sensitized with 1.5 mg/ml mouse monoclonal anti-dinitrophenyl (DNP) IgE (Yamasa Co., Tokyo, Japan) for 6 h at 37°C. Cells were washed and resuspended at a density of 8ϫ10 5 cells/ml in 50 ml of Tyrode's buffer (130 mM NaCl, 5 mM KCl, 1.4 mM CaCl 2 , 1 mM MgCl 2 , 5.6 mM glucose, 10 mM Hepes, and 0.1% BSA, pH 7.5), and stimulated with 100 ng/ml DNP-bovine serum albumin (BSA) at 37°C for 1 h. Samples were centrifuged and supernatants were collected. The cell pellets were solubilized with 0.5% Triton X-100 in Tyrode's buffer. The enzymatic activities of b-hexosaminidase in the supernatants and cell lysates were measured using p-nitrophenyl-2-acetamido-2-deoxy-b-D-glucopyranoside (Wako Pure Chemical Industries) in 0.1 M sodium citrate (pH 4.5) at 37°C for 1 h. The reaction was stopped by the addition of 0.2 M NaOH and 0.2 M glycine. Production of p-nitrophenol was detected by absorbance at 405 nm. The extent of degranulation was calculated by dividing p-nitrophenol absorbance in the supernatant with the sum of absorbance in the supernatant and cell lysate.
Viability Analysis by PI Staining mBMMCs pretreated by the test drugs for 24 h were washed with fluorescent activated cell sorter (FACS) buffer (1% BSA, 0.2% NaN 3 , PBS) twice, and then cells were resuspend with FACS buffer in polystyrene round-bottom tube. After stained by 2 mg/ml propidium iodide (PI), viability of cells was examined by using FACSCalibur.
Data Analysis Data are expressed as the meanϮS.E. Statistical comparisons were made using one-way ANOVA followed by Bonferroni/Dunn post-hoc tests for multiple comparisons. Probability values (p) of Ͻ0.05 were considered as statistically significant.
RESULTS AND DISCUSSION
Saireito and shosaikoto showed significant cytotoxicity to mBMMCs at 1 mg/ml (Fig. 1 ) and did not show inhibitory effect on the degranulation of mBMMCs at lower concentrations (our unpublished data). In contrast, goreisan did not exhibit the cytotoxicity at 1 mg/ml (Fig. 1) . Therefore, we focused on the examination of the direct effect of goreisan on mucosal-type mast cells. Interestingly, the degranulation of mBMMCs was significantly inhibited by treatment with goreisan (Ն0.32 mg/ml) in a dose-dependent manner (Fig. 2) .
Goreisan is composed of five medicinal plants; Poria, Polyporus, Atractylodis Lanceae Rhizoma, Alismatis Rhizoma and Cinnamomi Cortex. Thus, we investigated which medicinal plant had the inhibitory effect on the degranulation of mucosal mast cells. Among the five medicinal plants, Poria (Ն1 mg/ml), Polyporus (Ն1 mg/ml), and Cinnamomi Cortex (Ն0.32 mg/ml) significantly inhibited the degranulation of mBMMCs (Fig. 3) . Neither Poria nor Polyporus was cytotoxic to mBMMCs at a concentration 1 mg/ml, whereas pretreatment with 1 mg/ml Cinnamomi Cortex was cytotoxic (Fig. 4) . As assessed by flow cytometry to detect FceRI and c-kit, the surface expression levels of these receptors were not changed by treatment with Poria and Polyporus (our unpublished data).
Because the principal and common chemical compound in Poria and Polyporus is ergosterol, [12] [13] [14] the effect of ergosterol on the degranulation of mBMMCs was examined. By treating the cells with ergosterol suspension (Ն32 mM), the degranulation of mBMMCs was significantly inhibited in a dose-dependent manner (Fig. 5) . In the present evaluation system, 100 mM ergosterol was not toxic to the mBMMCs (our unpublished data). It has been reported that ergosterol, the principal sterol of most fungi, shows inhibitory activity against 12-O-tetradecanoylphorbol-13-acetate induced ear inflammation in mice. 15) In the present study, we demonstrated that ergosterol has the inhibitory effect on the activation of mBMMC. When goreisan was added after the sensitization of mBMMC with anti-DNP IgE, we could not observe the inhibitory effects of goreisan (data not shown), suggesting that goreisam and ergosterol negatively affected the activation process of mBMMC prior to the binding of IgE to FceRI on mucosal mast cells, which is different from the pharmacological mechanism of mast cell stabilizers.
In conclusion, our results suggest that Poria, Polyporus and their component ergosterol possess the inhibitory effect on the activity of mucosal-type mast cells, which may at least partly explain the therapeutic effect of saireito on UC. While further studies are needed to fully elucidate the mechanism of these inhibitory effects on mucosal-type mast cells, ergosterol, which is a principal component of these medicinal mashrooms may provide us a lead compound of a therapeutic agent for mucosal mast cell-related diseases. 
Fig. 5. Effect of Ergosterol on the Degranulation of Mast Cells
Ergosterol was dissolved in MeOH, diluted with medium, and used for culturing cells. mBMMCs were treated with ergosterol at the concentrations for 24 h and release of b-hexosaminidase was measured as described in Fig. 2 . Cells treated with or without MeOH were used as controls. * pϽ0.05 compared to cells treated with only MeOH.
